Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial
2011

Evaluating Carbon Ion Radiotherapy for Liver Cancer

Sample size: 33 publication Evidence: moderate

Author Information

Author(s): Stephanie E. Combs, Daniel Habermehl, Tom Ganten, Jan Schmidt, Lutz Edler, Iris Burkholder, Oliver Jäkel, Thomas Haberer, Jürgen Debus

Primary Institution: University Hospital of Heidelberg

Hypothesis

The study aims to determine the optimal dose of carbon ion radiotherapy for patients with advanced hepatocellular carcinoma (HCC).

Conclusion

The PROMETHEUS-01 trial will assess the safety and efficacy of carbon ion radiotherapy in treating advanced HCC.

Supporting Evidence

  • Carbon ion therapy has shown promising results in previous studies for treating liver cancer.
  • The study aims to find the maximum tolerated dose of carbon ion therapy for safety.
  • Patients will be monitored for toxicity and treatment response over a period of time.

Takeaway

This study is testing a new type of radiation therapy for liver cancer to see how much can be given safely and if it helps patients.

Methodology

The study is a single-center Phase I dose escalation trial evaluating carbon ion radiotherapy in patients with advanced HCC.

Limitations

The study is limited to a single center and may not be generalizable to all patient populations.

Participant Demographics

Patients must be adults with histologically confirmed HCC and liver-confined disease.

Digital Object Identifier (DOI)

10.1186/1471-2407-11-67

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication